[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

We are a science-driven global biotech company

Transforming Potential into Reality

Find out more

Pipeline

Latest News

Press Releases

2025.01.08

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

Chairman of the Board, Wei Fu, informed the Company of his intent to purchase up to $2,000,000 of the Company’s American Depository Shares (ADSs) ROCKVILLE, MD, January 8, 2024 – I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced […]

2025.01.06

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

Givastomig: a Claudin 18.2 (“CLDN18.2”) x 4-1BB bispecific antibody, will be the lead clinical program following the Company’s portfolio prioritization The Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose expansion study is […]

2024.11.21

I-Mab to Participate at the Piper Sandler Healthcare Conference

The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024 ROCKVILLE, MD, November 21, 2024 – I-Mab (NASDAQ: IMAB, the “Company”), a U.S.-based global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Piper Sandler 36th […]

View all Press Releases

Events

View All Events

Our Purposeful Journey to Bring Innovative Medicines to People We Serve

Founded

I-Mab was established in June 2016

Series A Financing

I-Mab completed Series A financing, raising $58 million

Merger & Series B Financing

Third Venture Biopharma and Tasgen merged to form I-Mab, raising $120 million in Series B Financing

Series C Financing

I-Mab successfully raised $227 million in Series C Financing

Nasdaq Listing

I-Mab was listed on the Nasdaq Global Market as a clinical-stage biotech company

AbbVie Global Partnership

I-Mab and AbbVie enter into global strategic partnership on development and commercialization of I-Mab's novel CD47 monoclonal antibody lemzoparlimab

Private Placement with Hillhouse Capital-Led Consortium

I-Mab entered into $523 million private placement agreement with Hillhouse Capital-led consortium

Global Footprint

I-Mab established its global footprint with 9 locations, including new R&D site in San Diego, and new GMP facility in Hangzhou

Jumpcan Partnership

I-Mab and Jumpcan entered into a strategic partnership for commercialization of I-Mab’s highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa in mainland China

U.S.-Based Biotech

I-Mab signed agreement to divest its assets and business operations in China, bringing a greater focus on the U.S. and ex-China markets